BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617. [PMID: 18499540 DOI: 10.1016/j.dld.2008.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Stasi C, Salomoni E, Arena U, Corti G, Montalto P, Bartalesi F, Marra F, Laffi G, Milani S, Zignego AL. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. Eur J Pharmacol. 2017;806:105-109. [PMID: 28414057 DOI: 10.1016/j.ejphar.2017.03.063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
2 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011;83:1909-16. [DOI: 10.1002/jmv.22199] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
4 Begini P, Cox MC, Angeletti S, Gigante E, Baccini F, Fonzo MD, Fave GD, Marignani M. Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: A case report. Scandinavian Journal of Infectious Diseases 2011;43:750-2. [DOI: 10.3109/00365548.2011.574149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011;43:589-95. [DOI: 10.1016/j.dld.2010.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
6 Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis. 2009;1:e2009025. [PMID: 21415959 DOI: 10.4084/mjhid.2009.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
7 Santantonio T, Fasano M. Resistance profile of entecavir in patients with chronic hepatitis B. Digestive and Liver Disease Supplements 2008;2:11-5. [DOI: 10.1016/s1594-5804(09)60005-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Digestive and Liver Disease 2012;44:49-54. [DOI: 10.1016/j.dld.2011.07.016] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
9 Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18:e212-e216. [PMID: 21692935 DOI: 10.1111/j.1365-2893.2011.01435.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wilder J, Patel K. The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl). 2014;7:107-114. [PMID: 24833926 DOI: 10.2147/mder.s46943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
11 Su CW, Wu JC, Lee SD. Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B? Hepatology 2008;48:1726-7; author reply 1727-8. [PMID: 18972445 DOI: 10.1002/hep.22520] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, Valvano MR, Abate ML, Gioffreda D, Caviglia GP, Rizzetto M, Andriulli A. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53:834-840. [PMID: 20800919 DOI: 10.1016/j.jhep.2010.06.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
13 Giannini EG, Marenco S, Boni S, Beltrame A, Nicolini LA, Taramasso L, Feasi M, Grasso A, De Leo P, Percario G, Bartolacci V, Artioli S, Viscoli C, Cassola G, Testa R, Anselmo M, Riccio G, Savarino V, Picciotto A. Therapeutic Management of Chronic Hepatitis B in Clinical Practice: A Region-wide Survey. Journal of Clinical Gastroenterology 2015;49:228-34. [DOI: 10.1097/mcg.0000000000000106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
14 Stasi C, Arena U, Vizzutti F, Zignego AL, Monti M, Laffi G, Corti G, Pinzani M. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool? Dig Liver Dis. 2009;41:863-866. [PMID: 19482565 DOI: 10.1016/j.dld.2009.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
15 Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy 2011;102:72-80. [DOI: 10.1016/j.healthpol.2010.09.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
16 Giannini EG, Torre F, Basso M, Feasi M, Boni S, Grasso A, De Leo P, Dodi F, Marazzi MG, Azzola E, Bartolacci V, Percario G, Beltrame A, Borro P, Savarino V, Picciotto A; Ligurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy. J Clin Gastroenterol 2009;43:1001-7. [PMID: 19318981 DOI: 10.1097/MCG.0b013e31818e876f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
17 Ganczak M, Szych Z, Korzeń M. Preoperative vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: a cross-sectional study. Vaccine 2009;27:3969-74. [PMID: 19389444 DOI: 10.1016/j.vaccine.2009.04.042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
18 Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat. 2010;17:624-630. [PMID: 20487257 DOI: 10.1111/j.1365-2893.2010.01318.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Zampino R, Pisaturo MA, Cirillo G, Marrone A, Macera M, Rinaldi L, Stanzione M, Durante-Mangoni E, Gentile I, Sagnelli E, Signoriello G, Miraglia Del Giudice E, Adinolfi LE, Coppola N. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015;14:75-82. [PMID: 25536644 DOI: 10.1016/s1665-2681(19)30803-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 1] [Article Influence: 4.1] [Reference Citation Analysis]
20 Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, Filice G, Levrero M, Mazzotta F, Pastore G, Piccinino F, Prati D, Raimondo G, Sagnelli E, Toti M, Brunetto M, Bruno R, Di Marco V, Ferrari C, Gaeta GB, Lampertico P, Marzano A, Pollicino T, Puoti M, Santantonio T, Smedile A. Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. Digestive and Liver Disease 2011;43:259-65. [DOI: 10.1016/j.dld.2010.10.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
21 Gaeta GB. Telbivudine: Taking into account baseline and on-therapy predictors. J Hepatol 2008;49:874-5. [PMID: 18814930 DOI: 10.1016/j.jhep.2008.08.008] [Reference Citation Analysis]
22 Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4(3): 37-45 [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
23 Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis. 2010;42:81-91. [PMID: 19748329 DOI: 10.1016/j.dld.2009.08.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
24 Marignani M, Marzano A, Begini P, Vitolo U, Luminari S, Levis A, Deli I, Gigante E, De Santis E, delle Fave G, Monarca B, Cox MC. Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. Leuk Lymphoma 2014;55:2564-71. [PMID: 24471911 DOI: 10.3109/10428194.2013.879712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A. Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2010;16:809-17. [DOI: 10.1016/j.bbmt.2009.12.533] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
26 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
27 Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2014;33:559-567. [PMID: 24081499 DOI: 10.1007/s10096-013-1985-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
28 Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, Fiore M, Sagnelli C, Pasquale G. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat. 2012;19:890-896. [PMID: 23121368 DOI: 10.1111/j.1365-2893.2012.01627.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
29 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
30 D'Andrea M, Nosotti L, Pimpinelli F, Dessanti ML, Paviglianiti A, Miglioresi L, Morrone A, Petti MC. The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy. Dig Liver Dis. 2009;41:839-840. [PMID: 19464241 DOI: 10.1016/j.dld.2009.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag 2009;5:177-85. [PMID: 19436619 DOI: 10.2147/tcrm.s3335] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Alberti A, Caporaso N. HBV therapy: guidelines and open issues. Dig Liver Dis. 2011;43 Suppl 1:S57-S63. [PMID: 21195373 DOI: 10.1016/s1590-8658(10)60693-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Marignani M, Canzoni M, D'Amelio R, De Santis E, Pecchioli A, Delle Fave G. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. Eur J Intern Med 2011;22:576-81. [PMID: 22075283 DOI: 10.1016/j.ejim.2011.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Niro GA, Gioffreda D, Fontana R. Hepatitis delta virus infection: Open issues. Digestive and Liver Disease 2011;43:S19-24. [DOI: 10.1016/s1590-8658(10)60688-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]